UNSPSC 51361506: Acetylglycinamide chloral hydrate

This classification denotes the acetylglycinamide form of an adjuvant analgesic with the molecular formula C2H3Cl3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 418M5916WG, chemically known as 2,2,2-trichloroethane-1,1-diol but generally known as chloral hydrate, which bears US NIH Compound Identifier 2707. European Medicines Agency schedules Chloral hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13324MIG.

World Health Organization schedules chloral hydrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, ACETYLGLYCINAMIDE CHLORAL HYDRATE remains the US FDA Preferred Term for this commodity. SMILES: none.

UNSPSC 51361506 Acetylglycinamide chloral hydrate is a Commodity code with a mismatch between its nominal scope and recent state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals and OTC products — none of which fall under acetylglycinamide chloral hydrate. The code shows little relevant recent activity; the opportunities appearing under it reflect broader pharmaceutical and drug-related procurement that the underlying taxonomy does not capture. State and local governments tagging naloxone systems, pharmacy benefit management initiatives, and generic drug supply contracts to a specific chemical compound code suggests either data entry error in the opportunity records or systematic miscoding at the source level.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of Minnesota and Oregon). The most recent opportunities are Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013 posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, serving Minnesota and Oregon. Without valid recent opportunities genuinely aligned to acetylglycinamide chloral hydrate, geographic concentration and market concentration signals cannot be reliably extracted from these records.